{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T03:09:01Z","timestamp":1763867341902,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.annder.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:44:22Z","timestamp":1676432662000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort"],"prefix":"10.1016","volume":"150","author":[{"given":"H.","family":"Arlegui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-1827","authenticated-orcid":false,"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-9132","authenticated-orcid":false,"given":"M.-A.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"De Rycke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Viguier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Beneton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0255","authenticated-orcid":false,"given":"P.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2023.01.005_b0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis Pathogenesis and Treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annder.2023.01.005_b0010","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.annder.2023.01.005_b0015","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annder.2023.01.005_b0025","article-title":"Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2023.01.005_b0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13054-020-02902-w","article-title":"Clinical determinants for fatality of 44,672 patients with COVID-19","volume":"24","author":"Deng","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.annder.2023.01.005_b0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09546634.2020.1742438","article-title":"Should patients stop their biologic treatment during the COVID-19 pandemic","volume":"31","author":"Bashyam","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2023.01.005_b0040","unstructured":"American Academy of Dermatology. Guidance on the use of biologic agents during COVID-19 outbreak 2020 [Available from: https:\/\/www.aad.org\/member\/practice\/managing\/coronavirus]."},{"key":"10.1016\/j.annder.2023.01.005_b0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.annder.2023.01.005_b0050","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/j.jaad.2020.04.002","article-title":"Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease","volume":"82","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0055","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD). Actualisation des recommandations pour les patients sous traitements immunosuppresseurs et bioth\u00e9rapies pour les maladies auto-immunes et inflammatoire. 2020 [Available from: https:\/\/www.sfdermato.org\/actualites\/liste-des-actualites.html]."},{"key":"10.1016\/j.annder.2023.01.005_b0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40257-020-00514-2","article-title":"Managing cutaneous immune-mediated diseases during the COVID-19 pandemic","volume":"21","author":"Torres","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/jdv.16863","article-title":"Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11739-020-02395-z","article-title":"Treat all COVID 19-positive patients, but do not forget those negative with chronic diseases","volume":"15","author":"Mauro","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.annder.2023.01.005_b0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000513398","article-title":"First-line biologic therapy and obesity in moderate-to-severe psoriasis: Results from the prospective multicenter cohort PsoBioTeq","volume":"237","author":"Assan","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2023.01.005_b0080","doi-asserted-by":"crossref","first-page":"adv00665","DOI":"10.2340\/actadv.v101.566","article-title":"Evolution of drug survival with biological agents and apremilast between 2012 and 2018 in psoriasis patients from the PsoBioTeq cohort","volume":"102","author":"Bettuzzi","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.annder.2023.01.005_b0085","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bjd.20585","article-title":"Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort","volume":"185","author":"Beylot-Barry","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.annder.2023.01.005_b0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jdv.15878","article-title":"Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French psoriasis registry PsoBioTeq","volume":"34","author":"Masson Regnault","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0095","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/jdv.14406","article-title":"Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the PsoBioTeq cohort","volume":"31","author":"Sbidian","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0105","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1111\/jdv.17450","article-title":"Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study","volume":"35","author":"Mahil","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0110","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1111\/jdv.16759","article-title":"Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece","volume":"34","author":"Vakirlis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0115","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/09546634.2020.1790485","article-title":"Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice","volume":"33","author":"Rodriguez-Villa Lario","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2023.01.005_b0120","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/09546634.2020.1770165","article-title":"A survey of psoriasis patients on biologics during COVID-19: a single centre experience","volume":"33","author":"Burlando","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2023.01.005_b0125","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1111\/jdv.16841","article-title":"Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy","volume":"34","author":"Talamonti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1684\/ejd.2021.4016","article-title":"Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital","volume":"31","author":"Ninosu","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0135","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/jdv.16771","article-title":"Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic","volume":"34","author":"Rob","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0140","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjd.20406","article-title":"Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic","volume":"185","author":"Penso","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0145","first-page":"581","article-title":"Patients with psoriasis and their compliance with medication","volume":"41","author":"Richards","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3121\/cmr.2013.1113","article-title":"Patient characteristics associated with medication adherence","volume":"11","author":"Rolnick","year":"2013","journal-title":"Clin Med Res"},{"key":"10.1016\/j.annder.2023.01.005_b0155","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/09546634.2021.1927947","article-title":"The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey","volume":"33","author":"Kartal","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2023.01.005_b0160","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0165","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","article-title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","volume":"161","author":"Ortonne","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.annder.2021.01.005","article-title":"Impact of the COVID-19 pandemic on children with psoriasis","volume":"148","author":"Beytout","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaad.2020.04.165","article-title":"COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy","volume":"83","author":"Carugno","year":"2020","journal-title":"Italy J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0185","first-page":"175","article-title":"Dermatological emergency unit, day-care hospital and consultations in time of COVID-19: the impact of teledermatology","volume":"36","author":"Brehon","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0190","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1111\/jdv.16630","article-title":"Teledermatology for COVID-19 cutaneous lesions: substitute or supplement?","volume":"34","author":"Skayem","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2023.01.005_b0195","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jamia\/ocaa067","article-title":"Telehealth transformation: COVID-19 and the rise of virtual care","volume":"27","author":"Wosik","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.annder.2023.01.005_b0200","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","article-title":"Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis","volume":"84","author":"Baniandres-Rodriguez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2023.01.005_b0205","doi-asserted-by":"crossref","first-page":"2001589","DOI":"10.1183\/13993003.01589-2020","article-title":"COVID-19 and the nicotinic cholinergic system","volume":"56","author":"Farsalinos","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.annder.2023.01.005_b0210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11739-020-02355-7","article-title":"Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?","volume":"15","author":"Farsalinos","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.annder.2023.01.005_b0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ntr\/ntaa188","article-title":"The paradox of the low prevalence of current smokers among COVID-19 patients hospitalized in nonintensive care wards: Results from an Italian multicenter case-control study","volume":"23","author":"Meini","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.annder.2023.01.005_b0220","article-title":"Lower rate of daily smokers with symptomatic COVID-19: a monocentric self-report of smoking habit study","volume":"8","author":"Miyara","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.annder.2023.01.005_b0225","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/ntr\/ntab004","article-title":"Impact of tobacco smoking on the risk of COVID-19: a large scale retrospective cohort study","volume":"23","author":"Paleiron","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.annder.2023.01.005_b0230","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/add.15276","article-title":"The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7)","volume":"116","author":"Simons","year":"2021","journal-title":"Addiction"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963823000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:39Z","timestamp":1758971439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963823000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0151963823000091"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2023.01.005","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}